
Lux Biosciences Inc. has submitted simultaneous regulatory filings to the FDA and the European Medicines Agency seeking marketing approval for an investigational drug, oral voclosporin (LUVENIQ or LX211), for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
